NCT00907140已完成不适用
Assessment of Changes in Pattern and Magnitude of Tumor FDG Uptake During Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients With Cervical Cancer
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- The overall goal of this pilot study is to evaluate the change in cervical tumor FDG heterogeneity and SUVmax during chemoradiation.
研究概览
简要总结
Rationale: Diagnostic procedures, such as positron emission tomography (PET) using fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients with cervical cancer
The purpose of this study is to evaluate the change in cervical tumor heterogenity as measured by FDG-PET/CT imaging.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Biopsy-proven cervical cancer. (FIGO stage-Ib2-IVa)
- •Able to receive chemoradiation therapy with Cisplatin.
- •Non-pregnant status in women of childbearing potential.
- •No other active cancer at the time of diagnosis of cervical cancer Patients cannot have received treatment for any malignancy, with the exception of non-melanoma skin cancer, in the past 5 years.
- •Patients with distant metastatic disease are eligible provided the estimated survival of the patient is at least 1 year.
- •Scheduled to undergo or have already undergone FDG-PET/CT imaging for clinical staging of cervical cancer at Barnes-Jewish Hospital Clinical PET Facility on a Biograph 40 PET/CT scanner
- •Able to give informed consent
排除标准
- •Patients with a known active malignancy other than cervical carcinoma.
- •Pregnant and breastfeeding patients.
- •Subjects whose tumors are not FDG avid on baseline standard of care FDG-PET/CT imaging
研究组 & 干预措施
Chemoradiation therapy
Other
干预措施: Positron Emission Tomography (Procedure)
结局指标
主要结局
The overall goal of this pilot study is to evaluate the change in cervical tumor FDG heterogeneity and SUVmax during chemoradiation.
时间窗: FDG PET/CT imaging is performed at: Baseline, 2 & 4 weeks of therapy, and 3 months after completing therapy
次要结局
- To correlate changed in FDG heterogeneity and SUVmax with response to therapy.(5 years)
研究者
Farrokh Dehdashti
Co-Principal Investigator
Washington University School of Medicine
研究点 (1)
Loading locations...
相似试验
已完成
不适用
PET Study in Patients With Non-Hodgkin LymphomaLymphomaNCT00712556Vanderbilt-Ingram Cancer Center55
已完成
不适用
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During SurgeryColorectal CancerNCT00004891Memorial Sloan Kettering Cancer Center149
已完成
不适用
FDG-PET/CT in the Evaluation of Patients With Suspected CholecystitisCholecystitisNCT00590395Alan D. Waxman, M.D.19
已完成
1 期
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or HypopharynxHead and Neck CancerNCT00757549Mayo Clinic30
已完成
不适用
Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a VeinUnspecified Adult Solid Tumor, Protocol SpecificThromboembolismNCT00964275University Hospital, Brest400